IOVA News and Press, Iovance Biotherapeutics Inc. From 04/16/24

2024-04-16 18:25:52 ET Summary Lyell Immunopharma, Inc.'s stock price has risen over 20% YTD and over 45% in the past 12 months. The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results ...

2024-04-11 10:10:03 ET More on Exelixis Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024 Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript Exelixis: 2024 Looking Good In The Mid-Term Exelixis Q4 2023 Earnings Preview Se...

2024-04-09 06:05:54 ET Summary Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering. The company has developed its own production capacity and aims to become a global leader in TIL th...

2024-04-05 05:03:00 ET If you're looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one ...

2024-03-25 14:29:08 ET Summary Iovance's tumor-infiltrating lymphocyte (TIL) product, Amtagvi, was recently approved by the FDA for the treatment of advanced melanoma patients who have failed a PD-1 blocking antibody. Initial numbers from the early days of the launch can be consid...

2024-03-24 23:25:36 ET Summary The rate of rise for big-cap tech stocks is slowing down or losing altitude, suggesting it may not be the best time to invest in them. The economy is growing, inflation is under control, and the Fed is committed to cutting rates, creating opportuniti...

2024-03-18 02:00:00 ET As great of an investment as Eli Lilly (NYSE: LLY) is during the age of Zepbound, its newest and hottest weight-loss drug, there are many other magnificent opportunities out there right now, and it'd be a disservice to your portfolio to ignore them entirely. ...

2024-03-17 19:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-07 06:01:00 ET On March 4, analyst Joseph Pantginis at HC Wainwright opined that shares of Iovance Biotherapeutics (NASDAQ: IOVA) would reach $32, an increase of 91% beyond its current price near $17. There are a handful of reasons to believe that Pantginis' estimate wil...

2024-03-06 04:42:00 ET Iovance Biotherapeutics (NASDAQ: IOVA) stock fell on Feb. 29, the day after it reported its fourth-quarter earnings, but that didn't stop Goldman Sachs analyst Andrea Tan from issuing a sunny outlook, raising her price target for the stock from $19 to $21....